Document Detail


Clarity and applicability of drug-drug interaction management guidelines: a systematic appraisal by general practitioners and community pharmacists in the Netherlands.
MedLine Citation:
PMID:  21751828     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background: Despite the availability and daily use of computerized drug-drug interaction surveillance systems, exposure to potentially relevant drug-drug interactions (DDIs) continues. DDI management guidelines are often inadequate and clear management options are lacking, which attributes to overriding of DDI signals. Although general criteria for the development and reporting of high-quality clinical practice guidelines have been identified, it appears these have not yet been applied to DDI management guidelines. Objectives: The aim of the study was to assess the clarity and applicability of guidelines for the management of potentially harmful DDIs. Methods: We selected 13 DDIs that are potentially harmful for patients and frequently occur in community pharmacy practice in the Netherlands. The clarity and applicability of the management guidelines of these DDIs were appraised using the appropriate two domains - 'Clarity and presentation' and 'Applicability', of the validated Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. The appraisal was performed by 12 community pharmacists and 12 general practitioners. The standardized domain scores and mean item scores for 'Clarity and presentation' and 'Applicability' were compared. Results: All DDI management guidelines were generally found to score well on 'Clarity and presentation', but poorly with respect to 'Applicability' (standardized domain scores 68.0 vs 26.1%). Within the domain 'Clarity and presentation', the item 'tools for application' received the lowest scores. Within the domain 'Applicability', cost implications, organizational barriers and key review criteria were all poorly documented. All guidelines presented non-directive advice using words such as 'consider' and 'regularly'. Conclusions: Developers of DDI management guidelines should take the appropriate domains of the AGREE Instrument into consideration in their development processes. The applicability of DDI management guidelines should be pretested before publishing. To improve guideline quality, more attention should particularly be paid to the available tools for applications and cost implications.
Authors:
Annemieke Floor-Schreudering; Peter A G M De Smet; Henk Buurma; Sonia Amini; Marcel L Bouvy
Related Documents :
21741758 - Beyond the conventional: meeting the challenges of landscape governance within the euro...
20469458 - A rationale for the current management of post-menopausal osteoporosis.
18028158 - Designing new institutions for implementing integrated disaster risk management: key el...
2363058 - Managing ecological upheavals: a third world perspective.
7982258 - The international consensus report on diagnosis and treatment of asthma: a call to acti...
14727738 - The discovery of pyridalyl: a novel insecticidal agent for controlling lepidopterous pe...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drug safety : an international journal of medical toxicology and drug experience     Volume:  34     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  683-90     Citation Subset:  IM    
Affiliation:
SIR Institute for Pharmacy Practice and Policy, Leiden, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-secti...
Next Document:  Delivery outcome after maternal use of drugs for migraine: a register study in sweden.